PMID- 19691907
OWN - NLM
STAT- MEDLINE
DCOM- 20100624
LR  - 20161020
IS  - 1469-5111 (Electronic)
IS  - 1461-1457 (Linking)
VI  - 13
IP  - 3
DP  - 2010 Apr
TI  - Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy 
      effective in generalized anxiety disorder. Data from a randomized, double-blind, 
      placebo- and active-controlled study.
PG  - 305-20
LID - 10.1017/S1461145709990423 [doi]
AB  - The efficacy and tolerability of extended-release quetiapine fumarate (quetiapine 
      XR) once-daily monotherapy in generalized anxiety disorder (GAD) was assessed. 
      This multicentre, double-blind, randomized, placebo- and active-controlled, phase 
      III trial consisted of a 1- to 4-wk enrolment/wash-out period and a 10-wk (8-wk 
      active treatment, 2-wk post-treatment drug-discontinuation) study period; 873 
      patients were randomized to 50 mg or 150 mg quetiapine XR, 20 mg paroxetine, or 
      placebo. Primary endpoint was change from randomization at week 8 in Hamilton 
      Rating Scale for Anxiety (HAMA) total score. At week 8, all active agents 
      produced significant improvements in HAMA total and psychic subscale scores vs. 
      placebo; HAMA somatic subscale scores were significantly reduced only by 150 mg 
      quetiapine XR. Significant separation from placebo (-2.90) in HAMA total score 
      was observed at day 4 for 50 mg quetiapine XR (-4.43, p<0.001) and 150 mg 
      quetiapine XR (-3.86, p<0.05), but not for paroxetine (-2.69). Remission (HAMA 
      total score 7) rates at week 8 were significantly higher for 150 mg quetiapine XR 
      (42.6%, p<0.01) and paroxetine (38.8%, p<0.05) vs. placebo (27.2%). The most 
      common adverse events (AEs) were dry mouth, somnolence, fatigue, dizziness, and 
      headache, for quetiapine XR, and nausea, headache, dizziness for paroxetine. A 
      lower proportion of patients reported sexual dysfunction with quetiapine XR [0.9% 
      (50 mg), 1.8% (150 mg)] than with placebo (2.3%) or paroxetine (7.4%). The 
      incidence of AEs potentially related to extrapyramidal symptoms was: quetiapine 
      XR: 50 mg, 6.8%, 150 mg, 5.0%; placebo, 1.8%; and paroxetine, 8.4%. Once-daily 
      quetiapine XR is an effective and generally well-tolerated treatment for patients 
      with GAD, with symptom improvement seen as early as day 4.
FAU - Bandelow, Borwin
AU  - Bandelow B
AD  - Department of Psychiatry and Psychotherapy, University of Goettingen, Germany. 
      Borwin.Bandelow@medizin.uni-goettingen.de
FAU - Chouinard, Guy
AU  - Chouinard G
FAU - Bobes, Julio
AU  - Bobes J
FAU - Ahokas, Antti
AU  - Ahokas A
FAU - Eggens, Ivan
AU  - Eggens I
FAU - Liu, Sherry
AU  - Liu S
FAU - Eriksson, Hans
AU  - Eriksson H
LA  - eng
SI  - ClinicalTrials.gov/NCT00322595
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20090820
PL  - England
TA  - Int J Neuropsychopharmacol
JT  - The international journal of neuropsychopharmacology
JID - 9815893
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Dibenzothiazepines)
RN  - 2S3PL1B6UJ (Quetiapine Fumarate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antipsychotic Agents/*therapeutic use
MH  - Anxiety Disorders/*drug therapy
MH  - Dibenzothiazepines/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Drug Delivery Systems/methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Psychiatric Status Rating Scales
MH  - Quetiapine Fumarate
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2009/08/21 09:00
MHDA- 2010/06/25 06:00
CRDT- 2009/08/21 09:00
PHST- 2009/08/21 09:00 [entrez]
PHST- 2009/08/21 09:00 [pubmed]
PHST- 2010/06/25 06:00 [medline]
AID - S1461145709990423 [pii]
AID - 10.1017/S1461145709990423 [doi]
PST - ppublish
SO  - Int J Neuropsychopharmacol. 2010 Apr;13(3):305-20. doi: 
      10.1017/S1461145709990423. Epub 2009 Aug 20.